ArticleJournal of veterinary internal medicine
Assessment of Exenatide Extended-Release for Maintenance of Diabetic Remission in Cats.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- iCatCare 2025 consensus guidelines on the diagnosis and management of diabetes mellitus in cats.Journal of feline medicine and surgery · 2025Guideline
- A two-center, randomized controlled trial to determine the effect of 12 weeks of caloric restriction with a novel diet in overweight cats with diabetes mellitus.Journal of veterinary internal medicine · 2026Article
- Spectrum of veterinary care in feline diabetes mellitus.Journal of feline medicine and surgery · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundInsulin-treated diabetic cats frequently achieve transient remission. The glucagon-like peptide-1 receptor agonist, exenatide extended-release (exenatide-ER), preserves β cell function in people with type 2 diabetes mellitus (DM).
objectivesInvestigate the effect of exenatide-ER on the duration of diabetic remission in cats. ANIMALS: Twenty-two client-owned cats with recent diabetic remissions.
methodsPlacebo-controlled, single-blinded study. Cats were assigned randomly to receive exenatide-ER (0.13 mg/kg) or saline injection SC, once monthly for 2 years or until DM relapsed. Cats were fed low-carbohydrate diets; weight control was actively supervised. Paired t-tests and Mann-Whitney were used to compare pre- versus post-study characteristics within groups and between group outcomes, respectively.
resultsTreatment groups (placebo, N = 10; exenatide-ER, N = 12) were similar in age, sex, and body weight upon inclusion. Thirteen cats completed the 2-year study without diabetic relapse. Nine cats (placebo, n = 4; exenatide-ER, n = 5) exited prematurely. Three of these exited because of DM relapse (placebo: N = 1, day 212; exenatide-ER: N = 2, days 553 and 558). There was no difference in remission duration between treatments (placebo: 669 [121-721]; exenatide-ER: 662 [28-735] days, p = 0.9). Median body weight decreased in both groups at study exit (placebo: -0.6 kg [-1.3 to +0.3], p = 0.03; exenatide-ER: -0.2 kg [-1.2 to +0.5], p = 0.02). Hemoglobin A1c remained unchanged on exenatide-ER (-0.05% [-6.9 to +2.1]) but increased on placebo (+2.3% [-1.7 to +4.4]; p = 0.03). CONCLUSIONS AND CLINICAL IMPORTANCE: Exenatide-ER contributed to the maintenance of glycemic control as reflected by hemoglobin A1c but did not affect remission duration. Management might have contributed to the extended remission duration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.